Two Survival Cuts, One Silent Substitution: The Lurbinectedin Joint Clinical Assessment

Le résumé fourni par la source

This methodological commentary examines the Joint Clinical Assessment (JCA) report of lurbinectedin combined with atezolizumab as maintenance therapy for extensive-stage small-cell lung cancer, based on the phase 3 IMforte trial. The JCA's evaluation rests on two overall survival data cuts: a confirmatory, hypothesis testing, statistically significant interim cut (hazard ratio 0.73, p=0.0174) and a mature, hypothesis generation, non-significant cut (hazard ratio 0.81). We identify two main critical methodological issues in the JCA's handling of these results. First, the JCA prefers the mature cut under a treatment-policy strategy that embeds subsequent crossover to lurbinectedin in the control arm, which is unavailable in routine European practice and dilutes the estimated treatment effect. The report lacks a decision-relevant, hypothetical-strategy analysis adjusting for this treatment switching. Second, the JCA discounts the positive interim result by assigning an "Unclear" risk-of-bias rating based on a late alpha-spending protocol amendment. This suspicion was left unresolved despite available data, the power to seek developer clarification, and regulatory findings from the European Medicines Agency (EMA) clearing the amendment as operational. Instead of a reasoned synthesis, the JCA performs a silent substitution of the mature cut for the interim. The report ignores the information both cut bring and questionably assesses the second cut as low risk of bias. To address these concerns, we recommend: complementing treatment-policy estimates with hypothetical-strategy analyses when trial crossover differs from European practice; resolving risk-of-bias concerns rather than leaving them "unclear"; engaging with prior regulatory evaluations; and providing graded certainty statements to reconcile divergent clinical results.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.